Loading…

Innoviva, Inc.INVACompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Collects royalties from GSK respiratory drugs and owns infectious-disease drugs including Xacduro for pneumonia.

Momentum weak 31
Mkt cap
$1.31B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$18.4M
20-day average traded
Fwd P/E
9.5×
forward earnings
ROIC−WACC
+9.7 pp
WACC 6.7%
Hurdle
-21 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · USD$18.40
1D+0.6%
1W-2.4%
1M-13.5%
3M-12.4%
6M-17.3%
YTD-8.0%
1Y-16.2%
ATR %3.4%
Beta0.34
52w lowhigh26.8% off high

What Innoviva does

Collects royalties from GSK respiratory drugs and owns infectious-disease drugs including Xacduro for pneumonia.

Receives a share of GSK's sales of its respiratory inhalers with none of the selling costs, since GSK sells the medicines; the rights stem from Innoviva's origin as Theravance, which developed them with GSK. Xacduro, an infection medicine, came with its 2022 purchase of Entasis.

Products and services

  • GSK royalty streams (Trelegy, Relvar, Anoro)
  • Xacduro (infectious disease)

Customers

  • Royalty counterparty: GSK

Where it sits in the supply chain

  • Pharma royalty/holding company
  • Royalty streams on partnered…
  • Infectious-disease drug ownership

What could go right

  • Continued GSK Trelegy/Ellipta franchise growth
  • Bolt-on royalty or asset purchases

What could go wrong

  • Dependent on GSK's respiratory-franchise performance
  • Infectious-disease assets smaller/riskier

Moat: narrow (IP / patents). Long-dated royalty contracts on GSK blockbuster respiratory drugs provide durable cash flow.

Headquarters: Waltham, Massachusetts, US · Founded: 1994 · Employees: 159

Named competitors

Innoviva at a glance

Size Innoviva (INVA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.31B, the 2061st largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.40 on 18 Nov 2026.

Performance Over six months the shares fell 17.3%, against -19.0% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 12.4% over the last twelve months (peer median +7.6%); the operating margin is 37.6% (peer median 0.8%).

Valuation It trades at 9.5× forward earnings against a peer median of 18.2× (2nd cheapest of 11).

Price implies For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -21 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.7 points above its cost of capital (6.7% WACC).

Short interest Short interest is 10.5% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026Peer median 84INVA 83
Six months, rebased to 100: Innoviva against the median of its 20 peers (local-currency closes).

Innoviva financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$452M$425M$373M$324M$345M
Revenue growth—+14%+15%-6%—
Gross profit$326M$308M$296M$246M$312M
EBITDA$211M$204M$207M$150M$227M
Net income$193M$271M$23.4M$180M$214M
Free cash flow$183M$196M$188M$141M$202M
Capital expenditure$955,000$1.13M$4.27M$411,000$67,000
Total debt$270M$269M$451M$449M$615M

Quarterly statements and history in the cockpit →

Innoviva competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%OCULMNKD688293LBRX301263068760002099002332300181NANOAMPH226950300204GPCR002020AVLNINVA6-month return →1-month return →
Up and to the right = strong over both horizons. Innoviva is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×200×400×MNKD688293301263002332300181300204000950INVARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Innoviva is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%688293068760002332300181AMPH688076002020INVAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Innoviva is the large dot.

Innoviva competitors and peer comparison

Head to head with its named competitors (INVA vs RPRX vs GSK.L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Innoviva INVA$1.31B-17%+12%38%9.5×-17.2%
Royalty Pharma RPRX$39.4B+29%+11%66%11.5×10.8%
GSK GSK.L$97.9B-3%+4%25%10.4×-0.1%

How Innoviva compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Innoviva against its 20 peers (data as of 18 Nov 2026)
MeasureINVAPeer medianRank in peer set
1-month return-13.5%-4.1%3rd lowest of 20
6-month return-17.3%-19.0%10th highest of 20
Distance from 52-week high-26.8%-38.9%4th highest of 20
Revenue growth (TTM)+12.4%+7.6%7th highest of 16
Operating margin37.6%0.8%highest of 16
Forward P/E9.5×18.2×2nd cheapest of 11
Growth the price implies (Req g, 7 yrs)-17.2%3.4%least demanding of 8
Growth delivered (Del g)+3.9%+18.1%2nd lowest of 8
Hurdle (Req g minus delivered)-21.1 pp-13.0 pp2nd least demanding of 8
ROIC minus cost of capital+9.7 pp-3.3 pphighest of 16
EV / EBITDA4.7×n/a—
Net debt / EBITDA-1.5×2.2×least indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Innoviva INVAUnited States$1.31B-17%+12%38%9.5×-17.2%+3.9%
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%n/an/an/a
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%48.6×25.9%+23.1%
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%60.7×n/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%n/a10.2%+18.1%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%n/an/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%13.0×3.9%+22.8%
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%n/an/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%n/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%12.1×-9.6%+4.6%
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a

Questions

Who are Innoviva's main competitors?
Named competitors: Royalty Pharma (RPRX), GSK (GSK.L). The cockpit's measured peer set (industry) also includes Ocular Therapeutix (OCUL), MannKind (MNKD), Windward Bio (WWB), Shanghai OPM Biosciences (688293.SS), LB Pharmaceuticals (LBRX), Guangdong Taienkang Pharmaceutical (301263.SZ).
Is Innoviva expensive compared with its peers?
On forward p/e it trades at 9.5× against a peer median of 18.2×, 2nd cheapest of 11 in its peer set. For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -21 pp: the price already allows for a slowdown.
How has Innoviva stock performed?
Over six months to 18 Nov 2026 the shares returned -17.3% against -19.0% for the median peer; over one year -16.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.